The Trump administration announced a 100% tariff on branded drug imports starting October 1, sparking anxiety across the biotech sector. The tariff exempts generic drugs and companies actively constructing manufacturing plants in the US, defined as breaking ground or underway construction. This aggressive move targets reliance on foreign-made pharmaceuticals and coincides with existing trade agreements capping tariffs on European imports at 15%. Industry stakeholders are evaluating the potential impacts amid ongoing regulatory investigations under Section 232.